EA200970874A1 - Антитела против склеростина - Google Patents

Антитела против склеростина

Info

Publication number
EA200970874A1
EA200970874A1 EA200970874A EA200970874A EA200970874A1 EA 200970874 A1 EA200970874 A1 EA 200970874A1 EA 200970874 A EA200970874 A EA 200970874A EA 200970874 A EA200970874 A EA 200970874A EA 200970874 A1 EA200970874 A1 EA 200970874A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sklerostin
antibodies against
antibodies
bone
osteoporosis
Prior art date
Application number
EA200970874A
Other languages
English (en)
Other versions
EA018204B1 (ru
Inventor
Эндрю Игорь Коритко
Дэвид Мэттью Маркис
Эрик Майкл Смит
Барбара Энн Свэнсон
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200970874A1 publication Critical patent/EA200970874A1/ru
Publication of EA018204B1 publication Critical patent/EA018204B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Предложены гуманизированные и гибридные антитела, которые специфически связывают склеростин человека и характеризуются высокой афинностью к нему и сильными нейтрализующими свойствами. Антитела по настоящему изобретению можно использовать для увеличения костной массы, минеральной плотности костной ткани и прочности костей, а также для лечения различных расстройств, например остеопороза у человека.
EA200970874A 2007-03-20 2008-03-11 Антитела против склеростина EA018204B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89581307P 2007-03-20 2007-03-20
PCT/US2008/056527 WO2008115732A2 (en) 2007-03-20 2008-03-11 Anti-sclerostin antibodies

Publications (2)

Publication Number Publication Date
EA200970874A1 true EA200970874A1 (ru) 2010-02-26
EA018204B1 EA018204B1 (ru) 2013-06-28

Family

ID=39756356

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970874A EA018204B1 (ru) 2007-03-20 2008-03-11 Антитела против склеростина

Country Status (32)

Country Link
US (3) US7744874B2 (ru)
EP (2) EP2131860B1 (ru)
JP (2) JP2010524846A (ru)
KR (1) KR101123487B1 (ru)
CN (1) CN101646457B (ru)
AU (1) AU2008229141B2 (ru)
BR (1) BRPI0809026A2 (ru)
CA (1) CA2682212C (ru)
CO (1) CO6230999A2 (ru)
CR (1) CR11004A (ru)
CY (1) CY1114784T1 (ru)
DK (1) DK2131860T3 (ru)
DO (1) DOP2009000223A (ru)
EA (1) EA018204B1 (ru)
EC (1) ECSP099658A (ru)
ES (1) ES2446293T3 (ru)
HK (1) HK1138790A1 (ru)
HR (1) HRP20140108T1 (ru)
IL (1) IL200437A0 (ru)
MA (1) MA31308B1 (ru)
MX (1) MX2009010051A (ru)
MY (1) MY149129A (ru)
NZ (1) NZ578870A (ru)
PL (1) PL2131860T3 (ru)
PT (1) PT2131860E (ru)
RS (1) RS53157B (ru)
SI (1) SI2131860T1 (ru)
SV (1) SV2009003374A (ru)
TN (1) TN2009000383A1 (ru)
UA (1) UA96474C2 (ru)
WO (1) WO2008115732A2 (ru)
ZA (1) ZA200906345B (ru)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395511B1 (en) 1998-11-27 2002-05-28 Darwin Discovery, Ltd. Nucleic acids encoding a novel family of TGF-β binding proteins from humans
US20040009535A1 (en) * 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
NZ544618A (en) 2003-06-16 2009-02-28 Celltech R & D Inc Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
PL3345607T3 (pl) 2006-12-29 2023-01-09 Ossifi-Mab Llc Sposoby modyfikowania wzrostu kości poprzez podanie antagonisty lub agonisty sost lub wise
WO2008115732A2 (en) * 2007-03-20 2008-09-25 Eli Lilly And Company Anti-sclerostin antibodies
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es) * 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
AU2008338464A1 (en) * 2007-12-14 2009-06-25 Amgen Inc. Method for treating bone fracture with anti-sclerostin antibodies
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
KR102469853B1 (ko) 2008-04-11 2022-11-22 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
WO2010115932A1 (en) 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
JP2013523153A (ja) 2010-04-07 2013-06-17 アッヴィ・インコーポレイテッド ＴＮＦ−α結合タンパク質
RU2012148716A (ru) 2010-04-16 2014-05-27 Новартис Аг Способы и композиции для улучшения оссеоинтеграции имплантата
EA027039B1 (ru) 2010-05-14 2017-06-30 Эмджен Инк. Композиции с высокой концентрацией антител
AU2011267869A1 (en) * 2010-06-14 2013-01-10 Vaccinex, Inc. Anti-VEGF antibodies and uses thereof
EP3757126A1 (en) 2010-11-05 2020-12-30 Novartis AG Methods of treating psoriatic arthritis using il-17 antagonists
JP5319651B2 (ja) * 2010-11-18 2013-10-16 日本電信電話株式会社 分析方法
AU2011337704B2 (en) 2010-11-30 2017-06-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
WO2012097313A2 (en) 2011-01-14 2012-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
WO2012118903A2 (en) 2011-03-01 2012-09-07 Amgen Inc. Bispecific binding agents
CN103517920B (zh) 2011-03-25 2018-04-17 安进公司 抗硬化蛋白(sclerostin)抗体晶体及其制剂
WO2012145417A1 (en) 2011-04-19 2012-10-26 Amgen Inc. Method for treating osteoporosis
JP2014515759A (ja) 2011-04-29 2014-07-03 ノバルティス アーゲー 扁平上皮がんを治療する方法関連出願
PT2739311T (pt) * 2011-08-04 2018-03-26 Amgen Inc Método para tratamento de defeitos de lacunas ósseas
MX2014004977A (es) * 2011-10-24 2014-09-11 Abbvie Inc Inmunoaglutinantes dirigidos contra esclerostina.
JP2014534218A (ja) 2011-10-24 2014-12-18 アッヴィ・インコーポレイテッド Ｔｎｆを標的とする免疫結合剤
RU2014121043A (ru) 2011-10-24 2015-12-10 Эббви Инк. Биспецифические иммуносвязывающие средства, направленные против tnf и il-17
EP2797953B1 (en) 2011-12-28 2020-06-03 Amgen Inc. Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
AU2013285488B2 (en) * 2012-07-05 2018-03-22 Ucb Pharma S.A. Treatment for bone diseases
US9221904B2 (en) 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
US20140065144A1 (en) * 2012-08-30 2014-03-06 National Cheng Kung University Use of il-20 antagonists for promoting bone fracture healing
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014118705A1 (en) 2013-01-31 2014-08-07 Novartis Ag Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
TWI636063B (zh) * 2013-03-08 2018-09-21 美國禮來大藥廠 結合ｉｌ－２３之抗體
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
US9763911B2 (en) 2013-12-12 2017-09-19 Mayo Foundation For Medical Education And Research Prostacyclin compositions for regulation of fracture repair and bone formation
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
MA41101A (fr) * 2014-12-03 2017-10-10 Lilly Co Eli Dispositif d'injection de médicament automatique comportant une indication audible de progression d'injection
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
WO2016109415A1 (en) * 2014-12-30 2016-07-07 Celgene Corporation Anti-cd47 antibodies and uses thereof
SI3269735T1 (sl) 2015-03-13 2020-12-31 Jiangsu Hengrui Medicine Co. Ltd. Protitelo proti sklerostinu, antigen-vezavni fragment in medicinska uporaba le-tega
WO2017149538A1 (en) 2016-03-01 2017-09-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (pvr)
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
CN110214021A (zh) 2016-08-08 2019-09-06 安进公司 使用抗硬化蛋白抗体改善结缔组织附着的方法
MX2019004862A (es) * 2016-10-28 2019-08-12 Lilly Co Eli Anticuerpos anti-rankl y usos de los mismos.
CA3041684C (en) * 2016-11-01 2023-09-26 Anaptysbio, Inc. Antibodies directed against programmed death- 1 (pd-1)
KR20190096409A (ko) * 2016-12-21 2019-08-19 메레오 바이오파마 3 리미티드 불완전 골형성증 치료에서의 항-스클레로스틴 항체의 용도
EP4219563A3 (en) 2017-01-09 2023-10-04 Tesaro, Inc. Methods of treating cancer with anti-pd-1 antibodies
JP7191833B2 (ja) * 2017-01-30 2022-12-19 中外製薬株式会社 抗スクレロスチン抗体およびその使用
US11530240B2 (en) 2017-06-09 2022-12-20 The Regents Of The University Of California Catheter injectable cyclic peptide pro-gelators for myocardial tissue engineering
US11498961B2 (en) 2017-07-27 2022-11-15 Jiangsu Hengrui Medicine Co., Ltd. SOST antibody pharmaceutical composition and uses thereof
KR20200138254A (ko) 2018-03-30 2020-12-09 암젠 인크 C-말단 항체 변이체
GB201810746D0 (en) 2018-06-29 2018-08-15 Mereo Biopharma 3 Ltd Use of sclerostin antagonist
AU2019316575A1 (en) 2018-08-10 2021-03-04 Amgen Inc. Method of preparing an antibody pharmaceutical formulation
CA3125033A1 (en) * 2019-01-22 2020-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
MX2022001805A (es) 2019-08-12 2022-06-08 Amgen Inc Formulaciones de anticuerpos anti-esclerostina.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US6395511B1 (en) 1998-11-27 2002-05-28 Darwin Discovery, Ltd. Nucleic acids encoding a novel family of TGF-β binding proteins from humans
JP2004520005A (ja) 2000-06-19 2004-07-08 エフ．ホフマン−ラ　ロシュ　アーゲー オステオレビン遺伝子多型性
US20040023356A1 (en) 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
AU2003283206A1 (en) * 2002-11-27 2004-06-18 Aventis Pharma Deutschland Gmbh A method and a system for establishing a quantity measure for joint destruction
NZ544618A (en) 2003-06-16 2009-02-28 Celltech R & D Inc Antibodies specific for sclerostin and methods for increasing bone mineralization
US20050033029A1 (en) 2003-06-30 2005-02-10 Jin Lu Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
WO2006046935A1 (en) 2004-10-22 2006-05-04 Applied Molecular Evolution, Inc Methods of optimizing antibody variable region binding affinity
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP2097450A2 (en) 2006-11-10 2009-09-09 Amgen Inc. Antibody-based diagnostics and therapeutics
WO2008115732A2 (en) * 2007-03-20 2008-09-25 Eli Lilly And Company Anti-sclerostin antibodies

Also Published As

Publication number Publication date
ES2446293T3 (es) 2014-03-07
EA018204B1 (ru) 2013-06-28
ZA200906345B (en) 2010-11-24
CO6230999A2 (es) 2010-12-20
US20090060924A1 (en) 2009-03-05
US20110250205A1 (en) 2011-10-13
RS53157B (en) 2014-06-30
HK1138790A1 (en) 2010-09-03
PT2131860E (pt) 2014-03-04
US20100221263A1 (en) 2010-09-02
MA31308B1 (fr) 2010-04-01
DK2131860T3 (da) 2014-01-13
CA2682212A1 (en) 2008-09-25
CN101646457A (zh) 2010-02-10
JP2013151504A (ja) 2013-08-08
NZ578870A (en) 2012-01-12
AU2008229141A1 (en) 2008-09-25
CA2682212C (en) 2014-05-06
TN2009000383A1 (en) 2010-12-31
BRPI0809026A2 (pt) 2014-09-23
IL200437A0 (en) 2010-04-29
JP2010524846A (ja) 2010-07-22
UA96474C2 (en) 2011-11-10
EP2131860B1 (en) 2013-12-18
HRP20140108T1 (hr) 2014-02-28
ECSP099658A (es) 2009-10-30
WO2008115732A2 (en) 2008-09-25
US7744874B2 (en) 2010-06-29
CR11004A (es) 2009-11-02
AU2008229141B2 (en) 2013-02-07
SI2131860T1 (sl) 2014-02-28
CY1114784T1 (el) 2016-12-14
JP5758933B2 (ja) 2015-08-05
MY149129A (en) 2013-07-15
KR101123487B1 (ko) 2012-03-23
US8257704B2 (en) 2012-09-04
EP2664346A1 (en) 2013-11-20
US7988970B2 (en) 2011-08-02
DOP2009000223A (es) 2009-10-15
EP2131860A2 (en) 2009-12-16
KR20090114462A (ko) 2009-11-03
CN101646457B (zh) 2013-05-01
WO2008115732A3 (en) 2008-12-11
MX2009010051A (es) 2009-10-12
SV2009003374A (es) 2011-01-10
PL2131860T3 (pl) 2014-05-30

Similar Documents

Publication Publication Date Title
EA200970874A1 (ru) Антитела против склеростина
CY1119994T1 (el) Συνθεσεις και μεθοδοι για αυξηση της μυϊκης μαζας και της μυϊκης δυναμης ανταγωνιζοντας ειδικα ton gdf8 και/ή την ακτιβινη α
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
EA201492149A1 (ru) St2-антигенсвязывающие белки
EA201001335A1 (ru) Антитела, направленные против ангиопоэтина-1 и ангиопоэтина-2, и их применение
EA201071300A1 (ru) Антитела к cxcr4
TN2010000140A1 (en) Compositions and methods for use antibodies against sclerostin
EA201491214A1 (ru) Композиции и способы применения антител, нацеленных на фактор p
EA201170205A1 (ru) Антитела, нейтрализующие цитомегаловирус человека, и их применение
MX2009006471A (es) Anticuerpo anti especifico de linfopoyetina estromal timica de diseño.
EA200802168A1 (ru) Гуманизированное антитело к с-kit
EA201000006A1 (ru) Способы и композиции для лечения аллергических заболеваний
MX2018007630A (es) Anticuerpos contra la metaloproteinasa de matriz 9.
WO2007042309A3 (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
EA201291161A2 (ru) Связывающие csf1r антитела
TW200745162A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
MX342413B (es) Anticuerpos para metaloproteinasa-9 de matriz.
EA200970251A1 (ru) Антитела к миостатину
EA201291067A1 (ru) Гуманизированные антигенсвязывающие белки к миостатину
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
EA201590247A1 (ru) Антитела к siglec-15
PH12014501931A1 (en) Antibodies to matrix metalloproteinase 9
NZ594682A (en) Fully human antibodies specific to cadm1
MX2013001267A (es) ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
EA201290360A1 (ru) Гуманизированные антитела против il-22ra человека

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU